| abstract |
The present invention provides methods of conducting RNAi using siRNAs that are sequentially administered as single-stranded oligonucleotides. The siRNAs can be canonical or have non-canonical ends. The compositions and methods of the invention can bypass activation of interferon pathways and yet still efficiently and specifically activate RNAi / gene silencing. In another embodiment, the siRNAs of the invention are modified to allow for the calculation of certain RNAi activities, e.g., RISC activity. The invention also provides methods of using the compositions in research, diagnostic, and therapeutic applications. |